CA2201750A1 - Complexe de chelates a perceptibilite elevee pour l'imagerie par resonance magnetique - Google Patents

Complexe de chelates a perceptibilite elevee pour l'imagerie par resonance magnetique

Info

Publication number
CA2201750A1
CA2201750A1 CA 2201750 CA2201750A CA2201750A1 CA 2201750 A1 CA2201750 A1 CA 2201750A1 CA 2201750 CA2201750 CA 2201750 CA 2201750 A CA2201750 A CA 2201750A CA 2201750 A1 CA2201750 A1 CA 2201750A1
Authority
CA
Canada
Prior art keywords
contrast agent
contrast
agent
signal intensity
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2201750
Other languages
English (en)
Inventor
Alan C. Rosenquist
Frank L. Lexa
Alexander V. Kachur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2201750A1 publication Critical patent/CA2201750A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/146—Peptides, e.g. proteins the peptide being a polyamino acid, e.g. poly-lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

L'invention concerne des agents de contraste possédant des caractéristiques de contraste améliorées et destinés à être utilisés dans des techniques d'imagerie non limitées à l'imagerie par résonance magnétique. Elle concerne également des procédés de synthèse et d'administration des agents de contraste. De plus, elle concerne un nécessaire adapté à la vente dans le commerce.
CA 2201750 1994-10-03 1995-10-03 Complexe de chelates a perceptibilite elevee pour l'imagerie par resonance magnetique Abandoned CA2201750A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31726794A 1994-10-03 1994-10-03
US08/317,267 1994-10-03

Publications (1)

Publication Number Publication Date
CA2201750A1 true CA2201750A1 (fr) 1996-04-11

Family

ID=23232878

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2201750 Abandoned CA2201750A1 (fr) 1994-10-03 1995-10-03 Complexe de chelates a perceptibilite elevee pour l'imagerie par resonance magnetique

Country Status (4)

Country Link
JP (1) JPH10509424A (fr)
AU (1) AU3946395A (fr)
CA (1) CA2201750A1 (fr)
WO (1) WO1996010359A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8647604B2 (en) 2006-01-25 2014-02-11 Uvic Industry Partnerships Inc. Lanthanide rich nanoparticles, and their investigative uses in MRI and related technologies

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000086538A (ja) * 1998-09-17 2000-03-28 Toshihiro Akaike Ｍｒｉ用造影剤
US7097826B2 (en) * 1999-12-23 2006-08-29 Health Research, Inc. Chlorin and bacteriochlorin-based difunctional aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
DE10325752A1 (de) * 2003-06-06 2004-12-30 Faustus Forschungs Cie. Translational Cancer Research Gmbh Lektin-Konjugate
WO2005080032A1 (fr) * 2004-02-20 2005-09-01 Kazunori Kataoka Procédé de fabrication de colloïde de fer, et micelle polymère porteuse de colloïde de fer
US20100191096A1 (en) * 2007-06-08 2010-07-29 Olav Tenstad Paramagnetic biomolecule complexes and uses thereof in the assessment of organ function
EP2327395A1 (fr) 2009-11-23 2011-06-01 Bracco Imaging S.p.A Procédé de préparation d'un complexe de gadobénate et de diméglumine sous forme solide
US10383958B2 (en) 2011-04-06 2019-08-20 Cedars-Sinai Medical Center Polymalic acid based nanoconjugates for imaging
CN110290816B (zh) * 2016-12-16 2022-09-30 澳大利亚国立大学 用于靶向施用的放射性标记材料

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
AU6621586A (en) * 1985-11-18 1987-06-02 University Of Texas System, The Polychelating agents for image and spectral enhancement (and spectral shift)
US5057313A (en) * 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
DE3806795A1 (de) * 1988-02-29 1989-09-07 Schering Ag Polymer-gebundene komplexbildner, deren komplexe und konjugate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5358702A (en) * 1990-04-10 1994-10-25 Unger Evan C Methoxylated gel particle contrast media for improved diagnostic imaging

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8647604B2 (en) 2006-01-25 2014-02-11 Uvic Industry Partnerships Inc. Lanthanide rich nanoparticles, and their investigative uses in MRI and related technologies

Also Published As

Publication number Publication date
JPH10509424A (ja) 1998-09-14
AU3946395A (en) 1996-04-26
WO1996010359A1 (fr) 1996-04-11

Similar Documents

Publication Publication Date Title
US5310539A (en) Melanin-based agents for image enhancement
EP0247156B1 (fr) Agents polychelateurs pour l'amelioration de l'image et du spectre (et pour derive spectrale)
EP0160552B1 (fr) Agents de contraste pour la formation d'images par résonance magnétique nucléaire
US6090408A (en) Use of polymerized lipid diagnostic agents
Konda et al. Specific targeting of folate–dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts
AU624132B2 (en) Contrast agents for magnetic resonance imaging
AU655175B2 (en) Diagnostic agents
US5260050A (en) Methods and compositions for magnetic resonance imaging comprising superparamagnetic ferromagnetically coupled chromium complexes
US5023072A (en) Paramagnetic/superparamagnetic/ferromagnetic sucrose sulfate compositions for magnetic resonance imaging of the gastrointestinal tract
US5336762A (en) Polychelating agents for image and spectral enhancement (and spectral shift)
AU628403B2 (en) Methods and compositions for magnetic resonance imaging
US5458870A (en) Compositions for magnetic resonance imaging using a manganese oxalate
CA2201750A1 (fr) Complexe de chelates a perceptibilite elevee pour l'imagerie par resonance magnetique
AU623408B2 (en) Magnetic particle-containing compositions
Runge et al. Experimental trials with Gd (DO3A)—a nonionic magnetic resonance contrast agent
Orang-Khadivi et al. New magnetic resonance imaging techniques for the detection of breast cancer
Weissleder et al. Polymeric contrast agents for MR imaging of adrenal glands
EP1106186A2 (fr) Bioconjugués non-covalents pour application dans la IRM
Amanlou et al. Magnetic resonance contrast media sensing in vivo molecular imaging agents: an overview
Adzamli et al. Macromolecular infarct-specific magnetic resonance contrast agents

Legal Events

Date Code Title Description
FZDE Dead